Compared with conventional T cells from healthy donors, cancer patient Vγ9Vδ2 T cells have a distinct inhibitory immune‐checkpoint receptor expression pattern associated with lower PD‐1, LAG‐3, and TIM‐3, which may be relatively resistant to ICB‐mediated inhibition, improving the efficacy of immunotherapy.[394]. This evidence concerns the gene HAVCR2 and cancer.